These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36220613)

  • 21. Seroconversion after a third COVID-19 vaccine is affected by rituximab dose but persistence is not in patients with rheumatoid arthritis.
    van der Togt CJT; Ten Cate DF; van den Bemt BJF; Rahamat-Langendoen J; den Broeder N; den Broeder AA
    Rheumatology (Oxford); 2023 Apr; 62(4):1627-1630. PubMed ID: 36000861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases.
    Tzioufas AG; Bakasis AD; Goules AV; Bitzogli K; Cinoku II; Chatzis LG; Argyropoulou OD; Venetsanopoulou AI; Mavrommati M; Stergiou IE; Pezoulas V; Voulgari PV; Katsimpari C; Katechis S; Gazi S; Katsifis G; Sfontouris CI; Georgountzos AI; Liossis SN; Papagoras C; Fotiadis DI; Skopouli FN; Vlachoyiannopoulos PG; Moutsopoulos HM
    J Autoimmun; 2021 Dec; 125():102743. PubMed ID: 34757289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study.
    Mrak D; Simader E; Sieghart D; Mandl P; Radner H; Perkmann T; Haslacher H; Mayer M; Koblischke M; Hofer P; Göschl L; Kartnig F; Deimel T; Kerschbaumer A; Hummel T; Kornek B; Thalhammer R; Stiasny K; Winkler S; Smolen JS; Aberle JH; Aletaha D; Heinz LX; Bonelli M
    Ann Rheum Dis; 2022 Dec; 81(12):1750-1756. PubMed ID: 35977809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?
    Baker D; MacDougall A; Kang AS; Schmierer K; Giovannoni G; Dobson R
    Clin Exp Immunol; 2022 May; 207(3):263-271. PubMed ID: 35553629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease modifying anti-rheumatic drugs: A cohort study and a meta-analysis.
    Auroux M; Laurent B; Coste B; Massy E; Mercier A; Durieu I; Confavreux CB; Lega JC; Mainbourg S; Coury F
    Joint Bone Spine; 2022 Oct; 89(5):105380. PubMed ID: 35490940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies.
    Wallach AI; Schiebel M; Picone MA
    Mult Scler Relat Disord; 2022 Jul; 63():103856. PubMed ID: 35636275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistent but atypical germinal center reaction among 3
    Stefanski AL; Rincon-Arevalo H; Schrezenmeier E; Karberg K; Szelinski F; Ritter J; Chen Y; Meisel C; Jahrsdörfer B; Ludwig C; Schrezenmeier H; Lino AC; Dörner T
    Front Immunol; 2022; 13():943476. PubMed ID: 36032111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease.
    Simon D; Tascilar K; Fagni F; Schmidt K; Krönke G; Kleyer A; Ramming A; Schoenau V; Bohr D; Knitza J; Harrer T; Manger K; Manger B; Schett G
    Ann Rheum Dis; 2022 Jul; 81(7):1023-1027. PubMed ID: 34819271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients.
    Georgieva ZG; Dӧffinger R; Kumararatne D; Coles AJ; McCarthy C
    Mult Scler; 2022 Jun; 28(7):1126-1130. PubMed ID: 34595965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups.
    Ferri C; Ursini F; Gragnani L; Raimondo V; Giuggioli D; Foti R; Caminiti M; Olivo D; Cuomo G; Visentini M; Cacciapaglia F; Pellegrini R; Pigatto E; Urraro T; Naclerio C; Tavoni A; Puccetti L; Varcasia G; Cavazzana I; L'Andolina M; Ruscitti P; Vadacca M; Gigliotti P; La Gualana F; Cozzi F; Spinella A; Visalli E; Dal Bosco Y; Amato G; Masini F; Pagano Mariano G; Brittelli R; Aiello V; Caminiti R; Scorpiniti D; Rechichi G; Ferrari T; Monti M; Elia G; Franceschini F; Meliconi R; Casato M; Iannone F; Giacomelli R; Fallahi P; Santini SA; Zignego AL; Antonelli A
    J Autoimmun; 2021 Dec; 125():102744. PubMed ID: 34781162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine.
    Belda F; Mora O; Lopez Martinez M; Torres N; Vivanco A; Christie R; Crowley M
    Vaccine; 2022 May; 40(22):2993-2998. PubMed ID: 35443917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
    Guven DC; Sahin TK; Akın S; Uckun FM
    Oncologist; 2022 Apr; 27(4):e357-e361. PubMed ID: 35274729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity of the mRNA-1273 and ChAdOx1 nCoV-19 vaccines in Asian patients with autoimmune rheumatic diseases under biologic and/or conventional immunosuppressant treatments.
    Liao HT; Tung HY; Chou CT; Tsai HC; Yen YN; Tsai CY
    Scand J Rheumatol; 2022 Nov; 51(6):500-505. PubMed ID: 35638589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to SARS-CoV-2 vaccines in patients receiving B-cell modulating antibodies for renal autoimmune disease.
    Arnold F; Huzly D; Tanriver Y; Welte T
    BMC Infect Dis; 2022 Sep; 22(1):734. PubMed ID: 36104663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose.
    Rossi AH; Ojeda DS; Varese A; Sanchez L; Gonzalez Lopez Ledesma MM; Mazzitelli I; Alvarez Juliá A; Oviedo Rouco S; Pallarés HM; Costa Navarro GS; Rasetto NB; Garcia CI; Wenker SD; Ramis LY; Bialer MG; de Leone MJ; Hernando CE; Sosa S; Bianchimano L; Rios AS; Treffinger Cienfuegos MS; Caramelo JJ; Longueira Y; Laufer N; Alvarez DE; Carradori J; Pedrozza D; Rima A; Echegoyen C; Ercole R; Gelpi P; Marchetti S; Zubieta M; Docena G; Kreplak N; Yanovsky M; Geffner J; Pifano M; Gamarnik AV
    Cell Rep Med; 2021 Aug; 2(8):100359. PubMed ID: 34308389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses.
    Saleem B; Ross RL; Bissell LA; Aslam A; Mankia K; Duquenne L; Corsadden D; Carter C; Hughes P; Nadat FA; Mulipa P; Lobb M; Clarke B; Mbara K; Morton R; Dibb S; Chowdhury R; Newton D; Pike A; Kakkar V; Savic S; DelGaldo F; Emery P
    RMD Open; 2022 Mar; 8(1):. PubMed ID: 35365569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients.
    Schietzel S; Anderegg M; Limacher A; Born A; Horn MP; Maurer B; Hirzel C; Sidler D; Moor MB
    RMD Open; 2022 Feb; 8(1):. PubMed ID: 35115385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge.
    Furlan A; Forner G; Cipriani L; Vian E; Rigoli R; Gherlinzoni F; Scotton P
    Front Immunol; 2021; 12():763412. PubMed ID: 34804051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COVID-19 Vaccine Response in People with Multiple Sclerosis.
    Tallantyre EC; Vickaryous N; Anderson V; Asardag AN; Baker D; Bestwick J; Bramhall K; Chance R; Evangelou N; George K; Giovannoni G; Godkin A; Grant L; Harding KE; Hibbert A; Ingram G; Jones M; Kang AS; Loveless S; Moat SJ; Robertson NP; Schmierer K; Scurr MJ; Shah SN; Simmons J; Upcott M; Willis M; Jolles S; Dobson R
    Ann Neurol; 2022 Jan; 91(1):89-100. PubMed ID: 34687063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.